Hematology — MCQs

Hematology Indian Medical PG Practice Questions and MCQs

Question 231: Autoimmune hemolytic anemia is seen in which of the following conditions?

A. Chronic myeloid leukemia (CML)
B. Chronic lymphocytic leukemia (CLL) (Correct Answer)
C. Acute lymphoblastic leukemia (ALL)
D. Acute myeloid leukemia (AML)

Explanation: The correct answer is Chronic Lymphocytic Leukemia (CLL) because it is the most common leukemia associated with autoimmune phenomena [3]. In CLL, the neoplastic B-cells are dysfunctional; they act as antigen-presenting cells that can trigger T-cell imbalance. This leads to the production of polyclonal autoantibodies by non-neoplastic B-cells against self-antigens on red blood cells [2]. * **Warm Autoimmune Hemolytic Anemia (W-AIHA):** This occurs in approximately 5–10% of CLL patients. It is typically mediated by IgG antibodies [3]. * **Evans Syndrome:** CLL can also present with a combination of AIHA and Immune Thrombocytopenic Purpura (ITP). **Why other options are incorrect:** * **CML:** This is a myeloproliferative neoplasm characterized by the Philadelphia chromosome [1]. It typically presents with massive splenomegaly and a high white cell count, but autoimmune cytopenias are extremely rare. * **AML & ALL:** These are acute leukemias characterized by a "maturation arrest" and bone marrow failure. Anemia in these conditions is usually due to marrow infiltration (myelophthisis) or chemotherapy, rather than an autoimmune process. **High-Yield Clinical Pearls for NEET-PG:** * **Direct Antiglobulin Test (Coombs Test):** This is the gold standard for diagnosing AIHA in CLL patients [3]. * **Richter Transformation:** If a CLL patient with AIHA suddenly develops rapid lymphadenopathy and systemic symptoms, suspect transformation into Diffuse Large B-Cell Lymphoma (DLBCL). * **Treatment:** While the primary treatment for CLL is targeted therapy (like Ibrutinib), AIHA within CLL is initially managed with **corticosteroids**.

Question 232: A patient has just been admitted to the hospital for observation. Based on the patient's laboratory results, what is the patient's primary problem? Hematocrit 45%, Hemoglobin 16 g/dL, Platelets 50 x 10^9/L.

A. Hemochromatosis
B. Deep vein thrombosis
C. Hepatic vein thrombosis
D. Recurrent nosebleeds (Correct Answer)

Explanation: **Explanation:** The laboratory results provided show a **normal Hematocrit (45%)** and **normal Hemoglobin (16 g/dL)**, but a significantly **low Platelet count (50 x 10⁹/L)**. This condition is known as **thrombocytopenia** [1]. 1. **Why "Recurrent nosebleeds" is correct:** Platelets are essential for primary hemostasis. When the platelet count drops below the normal range (150–450 x 10⁹/L), the patient becomes prone to mucosal bleeding [2]. Epistaxis (nosebleeds), petechiae, and gum bleeding are classic clinical manifestations of thrombocytopenia [2],[3]. A count of 50 x 10⁹/L is low enough to increase the risk of bleeding from minor trauma or spontaneously [1]. 2. **Why the other options are incorrect:** * **Hemochromatosis:** This is a disorder of iron overload. While it may lead to high hemoglobin in some contexts or cirrhosis in late stages, it is not primarily defined by isolated thrombocytopenia. * **Deep Vein Thrombosis (DVT) & Hepatic Vein Thrombosis (Budd-Chiari):** These are thrombotic (clotting) disorders. While conditions like Heparin-Induced Thrombocytopenia (HIT) or PNH can involve both clots and low platelets, isolated thrombocytopenia in a stable patient is statistically and clinically more likely to present with bleeding (like epistaxis) rather than a major venous thrombosis unless other risk factors are present. **High-Yield Clinical Pearls for NEET-PG:** * **Normal Platelet Range:** 1.5 to 4.5 lakh/mm³ (150–450 x 10⁹/L). * **Bleeding Risk:** Spontaneous bleeding usually does not occur until platelets are **<20 x 10⁹/L** [1]. Surgical bleeding risk increases when platelets are **<50 x 10⁹/L**. * **Primary vs. Secondary Hemostasis:** Platelet defects (quantitative or qualitative) lead to **mucocutaneous bleeding** (petechiae, purpura, epistaxis), whereas clotting factor deficiencies (e.g., Hemophilia) lead to **deep tissue bleeding** (hemarthrosis, hematomas) [2].

Question 233: Which of the following conditions does NOT present with microcytic hypochromic anemia?

A. Iron deficiency anemia
B. Anemia of chronic disease
C. Thalassemia
D. Aplastic anemia (Correct Answer)

Explanation: The correct answer is **D. Aplastic anemia**. **1. Why Aplastic Anemia is the correct answer:** Aplastic anemia is characterized by **pancytopenia** resulting from bone marrow failure (hypocellular marrow). Since the defect lies in the stem cell population and not in hemoglobin synthesis, the red blood cells produced are typically **normocytic and normochromic** (normal size and color). In some cases, it may even present as macrocytic due to increased erythropoietin stress on remaining stem cells, but it is **never** a classic cause of microcytic hypochromic anemia. **2. Analysis of Incorrect Options:** Microcytic hypochromic anemia (MCV <80 fL, MCHC <32%) occurs when there is a defect in **hemoglobin synthesis**. This can be remembered by the mnemonic **TAILS**: * **T - Thalassemia (Option C):** Defect in globin chain synthesis. It presents with very low MCV and a high RBC count (Mentzer Index <13). * **A - Anemia of Chronic Disease (Option B):** Initially normocytic, but can become microcytic over time due to hepcidin-mediated iron sequestration [1]. * **I - Iron Deficiency Anemia (Option A):** The most common cause; due to lack of iron for the heme ring [1]. * **L - Lead Poisoning:** Inhibits enzymes (ALAD and Ferrochelatase) in the heme pathway. * **S - Sideroblastic Anemia:** Defect in protoporphyrin synthesis. **3. NEET-PG High-Yield Pearls:** * **Mentzer Index:** (MCV/RBC count). If **<13**, suspect Thalassemia trait; if **>13**, suspect Iron Deficiency Anemia. * **Aplastic Anemia Gold Standard:** Bone marrow biopsy showing "dry tap" or "fatty replacement" (hypocellularity). * **Iron Studies:** In Anemia of Chronic Disease, **Ferritin is high/normal**, whereas in Iron Deficiency Anemia, **Ferritin is low** (the most sensitive initial test) [1].

Question 234: In a case of acute hemarthrosis in hemophilia, what is the recommended duration of treatment with factor VIII along with fresh frozen plasma?

A. 3 days
B. 7 days
C. 1 day
D. Until joint effusion subsides (Correct Answer)

Explanation: In acute hemarthrosis, Factor VIII replacement therapy (or Factor IX for Hemophilia B) should be initiated immediately. The treatment is not governed by a fixed number of days but is symptom-driven [1]. Therapy must continue until the joint effusion subsides, pain resolves, and the range of motion returns to baseline [1]. Stopping treatment prematurely while an effusion is still present increases the risk of re-bleeding and long-term synovial hypertrophy [1]. * Options A (3 days) and B (7 days): While many minor bleeds resolve within 3–7 days, these are arbitrary timeframes [1]. * Target Joint: Defined as a single joint in which 3 or more spontaneous bleeds have occurred within a 6-month period. * Factor Levels: For acute hemarthrosis, the goal is to raise Factor VIII levels to 40–60% of normal [1]. * Adjunctive Therapy: RICE (Rest, Ice, Compression, Elevation) is essential. However, aspirin and NSAIDs (except selective COX-2 inhibitors) must be avoided due to their effect on platelet function.

Question 235: A 25-year-old alcoholic man presents with easy fatigability and moderate pallor for the past six months. His Hb is 5.2 g/dL. What is the most appropriate initial treatment?

A. Iron supplementation
B. Pyridoxine supplementation (Correct Answer)
C. Ascorbic acid supplementation
D. Vitamin B12 supplementation

Explanation: ### Explanation **Correct Answer: B. Pyridoxine supplementation** The clinical presentation of a chronic alcoholic with severe anemia (Hb 5.2 g/dL) strongly suggests **Sideroblastic Anemia**. Alcohol is a common mitochondrial toxin that interferes with heme synthesis by inhibiting the enzyme **delta-aminolevulinate (δ-ALA) synthase**. **Pyridoxine (Vitamin B6)** is the essential cofactor for δ-ALA synthase. In alcoholics, malnutrition and the toxic effects of ethanol lead to B6 deficiency, resulting in impaired heme production and the formation of "ringed sideroblasts" (iron-laden mitochondria surrounding the nucleus of erythroid precursors). Supplementation with Pyridoxine can often reverse this condition by restoring enzyme activity. **Why other options are incorrect:** * **A. Iron supplementation:** Sideroblastic anemia is characterized by iron overload (high serum iron and ferritin) because iron is present but cannot be incorporated into hemoglobin. Adding iron would be contraindicated and potentially toxic. * **C. Ascorbic acid:** While Vitamin C aids iron absorption, it does not address the enzymatic defect in heme synthesis caused by alcohol. * **D. Vitamin B12:** While alcoholics can have macrocytic anemia due to B12 or folate deficiency, the classic association with alcohol-induced mitochondrial toxicity and the specific mechanism of heme inhibition points toward B6-responsive sideroblastic anemia. **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Smear:** Look for **dimorphic RBC population** (both hypochromic and normochromic cells) and **Pappenheimer bodies**. * **Bone Marrow:** The gold standard for diagnosis is **Prussian Blue staining**, which reveals **ringed sideroblasts** (>15% is diagnostic). * **Common Causes:** Apart from alcohol, consider **Isoniazid (INH)**, Lead poisoning, and Myelodysplastic Syndrome (MDS). * **Inherited Form:** The most common hereditary type is X-linked, involving a mutation in the *ALAS2* gene.

Question 236: Which one of the following laboratory tests differentiates leukemoid reaction from chronic myeloid leukemia?

A. Leukocyte alkaline phosphatase (LAP) (Correct Answer)
B. Leukocyte common antigen (LCA)
C. Myelo-peroxidase (MPO)
D. TRAP (tartrate resistant alkaline phosphatase)

Explanation: ### Explanation The differentiation between a **Leukemoid Reaction** (an exaggerated white blood cell response to infection or stress) and **Chronic Myeloid Leukemia (CML)** is a classic high-yield topic in hematology. **1. Why Leukocyte Alkaline Phosphatase (LAP) is correct:** LAP is an enzyme found within the secondary granules of mature neutrophils. * **In Leukemoid Reactions:** The neutrophils are functionally normal and "activated" by the inflammatory process, leading to a **high LAP score**. * **In CML:** The neutrophils are derived from a malignant clone (Philadelphia chromosome positive) and are functionally defective, resulting in a **low or absent LAP score**. * *Note:* The LAP score is also low in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hypophosphatasia. **2. Why the other options are incorrect:** * **Leukocyte Common Antigen (LCA/CD45):** This is a pan-leukocyte marker used in immunohistochemistry to differentiate lymphomas/leukemias from non-hematopoietic tumors (like carcinomas). It does not differentiate between types of myeloid proliferation. * **Myelo-peroxidase (MPO):** This enzyme is present in most myeloid cells [1]. It is used to differentiate Acute Myeloid Leukemia (AML - MPO positive) from Acute Lymphoblastic Leukemia (ALL - MPO negative), but it is present in both CML and leukemoid reactions. * **TRAP (Tartrate-Resistant Alkaline Phosphatase):** This is the specific diagnostic marker for **Hairy Cell Leukemia**. **Clinical Pearls for NEET-PG:** * **CML vs. Leukemoid Reaction:** Look for **Splenomegaly** and **Basophilia** in the question stem; both strongly favor CML over a leukemoid reaction. * **The Gold Standard:** While LAP was traditionally used, the definitive test for CML today is identifying the **t(9;22) translocation** (Philadelphia chromosome) or the **BCR-ABL1** fusion gene via FISH or PCR [3]. * **LAP Score in Polycythemia Vera:** The LAP score is typically **elevated** in Polycythemia Vera, helping distinguish it from secondary erythrocytosis [2].

Question 237: Which of the following is NOT true about aplastic anemia?

A. Splenomegaly (Correct Answer)
B. Reticulocytopenia
C. Thrombocytopenia
D. Neutropenia

Explanation: **Explanation:** **Aplastic Anemia** is a bone marrow failure syndrome characterized by **pancytopenia** and a **hypocellular bone marrow**. The fundamental pathology is the replacement of hematopoietic stem cells with fat, leading to a deficiency in all three blood cell lines. **Why Splenomegaly is the Correct Answer:** In true aplastic anemia, there is no extramedullary hematopoiesis or infiltrative process. Therefore, **splenomegaly is characteristically absent.** If a patient presents with pancytopenia and an enlarged spleen, clinicians must look for alternative diagnoses such as leukemia, myelofibrosis, lymphoma, or hypersplenism. The presence of splenomegaly essentially rules out a primary diagnosis of aplastic anemia. **Analysis of Incorrect Options:** * **B. Reticulocytopenia:** Since the bone marrow cannot produce new red blood cells, the reticulocyte count is low [1]. This is a hallmark of "hypoproliferative" anemia. * **C. Thrombocytopenia:** Low platelet counts are a standard feature of pancytopenia, leading to clinical signs like petechiae, purpura, and mucosal bleeding [2]. * **D. Neutropenia:** A decrease in absolute neutrophil count (ANC) is a defining feature. The severity of aplastic anemia (Camitta Criteria) is largely determined by the degree of neutropenia (e.g., ANC <500/µL for "Severe"). **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Bone marrow aspiration and biopsy showing **hypocellularity** (increased fat spaces). * **Peripheral Smear:** Shows normocytic normochromic anemia with no abnormal cells (no blasts, no teardrop cells). * **Treatment of Choice:** For patients <40 years with a matched sibling donor, **Bone Marrow Transplant** is preferred. For older patients or those without a donor, **Immunosuppressive Therapy (IST)** with Antithymocyte Globulin (ATG) and Cyclosporine is used. * **Drug Association:** Chloramphenicol is the most common drug historically associated with idiosyncratic aplastic anemia.

Question 238: What is the treatment of choice in hairy cell leukemia?

A. Steroid
B. Cladribine (Correct Answer)
C. Splenectomy
D. Pentostatin

Explanation: Explanation: **Hairy Cell Leukemia (HCL)** is a rare B-cell lymphoproliferative disorder characterized by pancytopenia, massive splenomegaly, and "hairy" cytoplasmic projections on peripheral smear. **Why Cladribine is the Correct Answer:** The treatment of choice for HCL is **Cladribine (2-Chlorodeoxyadenosine or 2-CdA)**. It is a purine nucleoside analog that is resistant to adenosine deaminase, leading to the accumulation of toxic nucleotides in B-cells. A single 7-day course of Cladribine induces complete remission in over 80-90% of patients, making it the gold standard first-line therapy. **Analysis of Incorrect Options:** * **Steroids (A):** Unlike in CLL or autoimmune hemolytic anemias, steroids have no significant role in treating the underlying malignancy in HCL and may increase the risk of opportunistic infections. * **Splenectomy (C):** Historically used to manage cytopenias and massive splenomegaly, it is now reserved for refractory cases or emergencies (e.g., splenic rupture). It is no longer the first-line treatment. * **Pentostatin (D):** Also a purine analog (adenosine deaminase inhibitor) and highly effective in HCL. However, **Cladribine** is preferred due to its shorter treatment duration and slightly better safety profile. **High-Yield Clinical Pearls for NEET-PG:** * **Marker of choice:** CD103 (most specific), CD11c, CD25, and Annexin A1. * **Genetic Mutation:** **BRAF V600E** mutation is present in nearly 100% of cases. * **Bone Marrow:** Often results in a **"Dry Tap"** due to increased reticulin fibrosis. * **Stain:** Tartrate-Resistant Acid Phosphatase (**TRAP**) positive. * **Clinical Hint:** Look for a patient with massive splenomegaly but **absent lymphadenopathy** (a classic HCL feature).

Question 239: Waldenstrom's macroglobulinemia is characterized by which of the following findings, except?

A. IgE secreting clone of plasma cells (Correct Answer)
B. Hyperviscosity symptoms
C. Hepatosplenomegaly
D. Lymphadenopathy

Explanation: **Explanation:** **Waldenström’s Macroglobulinemia (WM)** is a low-grade B-cell lymphoma characterized by the proliferation of **lymphoplasmacytic cells** that secrete a monoclonal **IgM** protein [1]. **1. Why Option A is the correct answer (The Exception):** WM is defined by the secretion of **IgM**, not IgE [1]. The presence of an IgE-secreting clone is extremely rare in plasma cell dyscrasias and is typically associated with IgE Multiple Myeloma, not WM. In WM, the "macroglobulin" refers specifically to IgM, which is the largest immunoglobulin pentamer. **2. Analysis of Incorrect Options (Findings present in WM):** * **Hyperviscosity symptoms (Option B):** Because IgM is a large pentameric molecule, high levels significantly increase blood viscosity. This leads to the classic triad of mucosal bleeding, visual disturbances (fundoscopic "sausage-link" veins), and neurological symptoms (headache, dizziness) [1]. * **Hepatosplenomegaly and Lymphadenopathy (Options C & D):** Unlike Multiple Myeloma, which is primarily confined to the bone marrow and causes lytic bone lesions, WM is a **lymphoproliferative disorder**. Therefore, infiltration of the reticuloendothelial system is common, leading to enlarged lymph nodes, liver, and spleen [1]. **Clinical Pearls for NEET-PG:** * **Hallmark Mutation:** Over 90% of patients possess the **MYD88 L265P** mutation. * **Bone Marrow:** Shows infiltration by **lymphoplasmacytic cells** (a mix of B-cells, plasma cells, and intermediate forms) [1]. * **Distinction from Multiple Myeloma:** WM does **not** typically cause lytic bone lesions or hypercalcemia. * **Treatment of Choice for Hyperviscosity:** Emergency **plasmapheresis** to rapidly lower IgM levels [1].

Question 240: Which is the most common preceding infection in bone marrow failure syndromes?

A. Parvovirus B19
B. Epstein-Barr virus
C. Human Immunodeficiency Virus
D. Hepatitis virus (Correct Answer)

Explanation: The correct answer is **Hepatitis virus**. In the context of bone marrow failure syndromes (specifically Acquired Aplastic Anemia), viral infections are a well-recognized trigger. Among these, **Hepatitis-associated aplastic anemia (HAAA)** is the most common post-viral syndrome. It typically presents as severe aplastic anemia occurring 2–3 months after an episode of acute hepatitis. Interestingly, in most cases, the hepatitis is "seronegative" (Non-A, Non-B, Non-C, Non-E), though Hepatitis B and C can occasionally be implicated. The pathophysiology involves a T-cell mediated immune attack on hematopoietic stem cells triggered by the viral infection. **Analysis of Incorrect Options:** * **Parvovirus B19:** While famous for causing hematologic issues, it typically causes **Pure Red Cell Aplasia (PRCA)** or transient aplastic crises in patients with underlying hemolytic anemias (like Sickle Cell) [1]. It does not usually cause global bone marrow failure (pancytopenia) [1]. * **Epstein-Barr virus (EBV):** EBV is associated with various hematologic malignancies and hemophagocytic lymphohistiocytosis (HLH), but it is a much less frequent cause of primary aplastic anemia compared to hepatitis viruses. * **Human Immunodeficiency Virus (HIV):** HIV commonly causes cytopenias due to direct marrow suppression or opportunistic infections, but it is not the classic "most common" preceding infection linked to the clinical syndrome of idiopathic aplastic anemia. **High-Yield Pearls for NEET-PG:** * **HAAA** typically affects young males and is often fatal if untreated. * The most common cause of Acquired Aplastic Anemia overall is **Idiopathic** (unknown). * **Drug-induced:** Chloramphenicol is the most notorious drug (idiosyncratic reaction). * **Gold Standard Investigation:** Bone marrow aspiration and biopsy (shows "dry tap" and fatty replacement). * **Treatment of Choice:** Bone marrow transplant (if <40 years) or Immunosuppressive therapy (Antithymocyte globulin + Cyclosporine).

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?